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SObjective(s):We evaluated a large series of patients undergoing robotic lobectomy for the treatment of early-
stage non–small cell lung cancer (NSCLC) to assess long-term oncologic efficacy.
Methods: A multi-institutional retrospective review of patients undergoing robotic lobectomy for NSCLC was
performed. Robotic lobectomy was performed in a manner consistent with the Cancer and Leukemia Group B
(CALGB) consensus video-assisted thoracic surgery (VATS) lobectomy technique using a robotic surgical sys-
tem. Perioperative outcomes and long-term follow-up were recorded prospectively, and survival was calculated
from the date of surgery to last follow-up.
Results: From November 2002 through May 2010, a total of 325 consecutive patients underwent robotic lobec-
tomy for early-stage NSCLC at 3 institutions. The median age of patients was 66 years (range, 30-87 years), and
37% (120) were female. The majority were in clinical stage I (IA, 247; IB, 63). Conversion rate to thoracotomy
was 8% (27/325). Overall morbidity rate was 25.2% (82/325), and major complication rate was 3.7% (12/325).
There was 1 in-hospital death (0.3%), and the median length of stay was 5 days (range, 2-28 days). Pathologic
stage distribution was 54% (176) IA, 22% (72) IB, 13% (41) IIA, 5% (15) IIB, and 6% (21) IIIA.With amedian
follow-up of 27 months, overall 5-year survival was 80% (95% confidence intervals [CI]¼ 73-88), and by path-
ologic stage, 91% (CI ¼ 83-99) for stage IA, 88% (CI ¼ 77-98) for stage IB, and 49% (CI ¼ 24-74) for all
patients with stage II disease. Overall 3-year survival for patients with stage IIIA disease was 43% (CI¼ 16-69).
Conclusions: Robotic lobectomy for early-stage NSCLC can be performed with low morbidity and mortality.
Long-term stage-specific survival is acceptable and consistent with prior results for VATS and thoracotomy.
(J Thorac Cardiovasc Surg 2012;143:383-9)G
TLung cancer remains one of the deadliest cancers world-
wide.1 With aging and growth of the population combined
with the persistence of cigarette smoking and the potential
widespread adoption of computed tomographic lung cancer
screening,2 therewill be an increasing number of early-stage
lung cancers appropriate for surgical resection. Lobectomy
performed by minimally invasive video-assisted thoracic
surgery (VATS) has proven to be feasible and oncologically
acceptable for isolated non–small cell lung cancer
(NSCLC).3-5 However, despite multiple studies showing
this and clear benefits over thoracotomy, such as decreased
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The Journal of Thoracic and Cadecreased pain,8 and improved delivery and tolerance of ad-
juvant chemotherapy,9 VATS lobectomy has not become
widely used. Indeed, a VATS approach has recently been re-
ported to have been used in less than 6% to 20% of all lobec-
tomies performed in the United States.10,11 The reasons for
this are not entirely clear but may be related to technical
limitations, such as 2-dimensional imaging and limited ma-
neuverability of instrumentation.
A robotic surgical system has been developed to address
some of these limitations. It has 3-dimensional, high-
definition imaging, instrumentation with 7 degrees of free-
dom, and a master–slave surgical cart (da Vinci; Intuitive
Surgical, Sunnyvale, Calif). A handful of small series
have reported similar techniques of robotic lobectomy
showing acceptable perioperative results,12-15 but there is
no large experience of totally robotic lobectomy
evaluating both perioperative and long-term oncologic out-
comes in patients with lung cancer.
The aims of this study are to evaluate a large cohort of pa-
tients who underwent robotic lobectomy to analyze both the
perioperative and long-term survival results and determine
whether it has an oncologically acceptable role in the surgi-
cal management of early NSCLC.
METHODS
A multicenter retrospective cohort trial was performed using prospec-
tively collected data from the thoracic surgery divisions of 3 institutions:rdiovascular Surgery c Volume 143, Number 2 383
Abbreviations and Acronyms
CALGB ¼ Cancer and Leukemia Group B
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
VATS ¼ video-assisted thoracic surgery
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SMemorial Sloan-Kettering Cancer Center, New York, New York, The Eu-
ropean Institute of Oncology, Milan, Italy, and Ospedale Cisanello, Pisa,
Italy. The study was approved by the institutional review board of each in-
stitution, and a data transfer agreement was made. Eligible patients were
those with biopsy-proven or suspected primary NSCLC with no evidence
of locally advanced or extrathoracic disease based on computed tomogra-
phy (CT) of the chest, whole-body positron emission tomography/CT, and
mediastinoscopy (select cases) who subsequently underwent attempted ro-
botic lobectomy for primary NSCLC. Patients with carcinoid tumor, small
cell lung cancer, benign or metastatic lesions, and those not undergoing lo-
bectomy were excluded. Information regarding preoperative characteris-
tics, operative details, hospital course, pathologic findings, and
postoperative follow-up were recorded prospectively and sent to 1 institu-
tion (Milan) for analysis.
Technique of Robotic Lobectomy
At each institution the indications for robotic lobectomy are identical to
those for VATS lobectomy—lesions isolated to the hemithorax, resectable
by lobectomy, in patients with adequate cardiopulmonary reserve. Each
surgeon (B.P., G.V., and F.M.) performed robotic lobectomy using a tech-
nique that conformed to the Cancer and Leukemia Group B (CALGB)
39802 consensus report for VATS lobectomy: use of non–rib-spreading in-
cisions with the largest incision no greater than 8 cm, videoscopic guid-
ance, and traditional hilar dissection.16 The detailed technical aspects
have been reported previously12,13,15 and will not be reviewed here. At 2
centers (Milan and Pisa) a 4-arm approach was used, whereas at the third
center (New York) a 3-arm technique was employed. All patients under-
went systematic mediastinal lymph node dissection. Patients gave written
informed consent to undergo robotic surgery, and operative times were
measured from first incision to closure. Conversion was defined as use of
a rib-spreading thoracotomy at any point after docking of the robot to
the patient and initiation of robotic dissection. Complications were re-
corded prospectively and categorized by the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0 (http://
ctep.cancer.gov/reporting/ctc.html) as either minor (grades 1 and 2) or ma-
jor (grade 3 or higher). Clinical and pathologic staging was performed us-
ing the seventh edition of the TNM classification.17
Surveillance and Follow-up
At each institution patients were followed up postoperatively for lung
cancer surveillance at least every 6 months for the initial 2 years with his-
tory, physical examination, blood work, and CT chest, and annually there-
after. Patients who did not return for follow-up evaluation were contacted
by telephone, or their status was checked by the Social Security Death In-
dex in the case of patients from the United States. Survival was calculated
from the date of surgery to the date of death or last follow-up. Survival es-
timates were calculated with the Kaplan-Meier method and compared by
the log–rank test. All analyses were performed with SAS statistical soft-
ware version 8.2 (SAS Institute, Inc, Cary, NC).
RESULTS
From November 2002 through May 2010, 325 patients
underwent robotic lobectomy for primary NSCLC at 3384 The Journal of Thoracic and Cardiovascular Surgcenters. There were 123 consecutive patients from the cen-
ter in New York during the study period, 82 patients from
the center in Milan from November 2006 through May
2010, and 120 patients from the center in Pisa from January
2004 through May 2010. Table 1 shows the patient charac-
teristics. There was a small preponderance of men, and
84% were former or current smokers. Over half of the pro-
cedures were upper lobectomies (right upper lobe, 92; left
upper lobe, 75), and 1 patient underwent bilobectomy (right
upper and middle lobes) for an upper lobe tumor invading
across the horizontal fissure. The majority of cases were
subtypes of adenocarcinoma (73%). Most patients had clin-
ical stage I disease (IA, 247; IB, 63) and had no preoperative
therapy. One patient had stage IIIA (N2) disease on the basis
of mediastinoscopy and received induction chemotherapy.
In all, 14% (45/325) of patients underwent preresection
mediastinoscopy.
Table 2 details the perioperative results of the robotic se-
ries. Median operative time was 3.5 hours. There were no
intraoperative deaths, and the conversion rate to thoracot-
omywas 8% (27/325). The reasons for conversion are listed
in Table 3. Three (0.9%) patients had conversion for minor
bleeding that did not require intraoperative or postoperative
transfusion. Overall morbidity rate was 25.2% (82/325) and
was not different between centers (New York, 26%; Milan,
27%; Pisa, 23%). Twelve (3.7%) patients had major com-
plications, including bronchopleural fistula (2), pulmonary
embolism (3), acute renal insufficiency (3), hemorrhage
(2), and myocardial infarction (2). Supraventricular tachy-
cardia was the most common postoperative complication,
occurring in 37 (11.4%) patients. Median chest tube dura-
tion was 3 days (range, 1-23 days), and length of stay was
5 days (range, 2-28 days). There was 1 in-hospital death
in a patient in whom acute renal insufficiency developed
followed by a pulmonary embolism and death on postoper-
ative day 12.
Seventy-six percent (248/325) of patients had pathologic
stage I disease (IA, 176; IB, 72), and in 68 (21%) patients
the severity of disease was upstaged (Table 2). The median
tumor size was 2.2 cm (range, 0.7-10.2 cm), and the median
number of lymph node stations dissected was 5 (range, 2-8).
Sixty-one (19%) patients had metastatic nodal disease, and
67 patients received adjuvant cytotoxic chemotherapy. At
a median follow-up of 27 months, 32 (10%) patients had
had recurrence, with 25 dead of their disease. The majority
(72%) of recurrences were distant (distant only, 17; locore-
gionalþdistant, 6), and 28% (9/32) were locoregional only.
Overall 5-year survival for the group was 80% (Figure 1,
A), and stage-specific survival is shown in Figure 1, B.
DISCUSSION
With the continued growth and aging of the population
and the likely acceptance of low-dose chest CT screening
of high-risk populations, the number and proportion ofery c February 2012
TABLE 1. Patient characteristics
Category Result
Age (y), median (range) 66 (30-87)
Male gender 204 (63%)
Smoking status
Unknown 3 (1%)
Never 50 (15%)
Former/current 272 (84%)
FEV1 (% pred), median (range) 95 (34–166)
DLCO (% pred), median (range) 87 (11–196)
Primary tumor location
RUL 92 (28%)
RML 29 (9%)
RLL 71 (22%)
RUL/ML 1 (0.3%)
LUL 75 (23%)
LLL 57 (18%)
Histology
Adenocarcinoma 239 (73%)
Squamous cell carcinoma 74 (23%)
Other 12 (4%)
FEV1, Forced expiratory volume in the first second; DLCO, diffusing capacity of the
lung for carbon monoxide; RUL, right upper lobe; RML, right middle lobe; RLL, right
lower lobe; LUL, left upper lobe; LLL, left lower lobe.
TABLE 3. Reasons for conversion to thoracotomy
No. Percent
Incomplete fissures 9 2.8
Adhesions 7 2.2
Anatomic 3 0.9
Bleeding 3 0.9
Oncologic 2 0.6
Adenopathy 1 0.3
Tumor location 1 0.3
Loss of lung isolation 1 0.3
Total 27 8.3
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Searly-stage lung cancers diagnosed annually is likely to in-
crease. Numerous reports from high-volume centers of ex-
cellence have shown that minimally invasive VATS
lobectomy can be a feasible and safe alternative to thoracot-
omy lobectomy with additional benefits that include shorter
length of chest tube duration and hospital stay, lower rate of
major complications, decreased acute postoperative pain,
and enhanced recovery and tolerance of adjuvant ther-
apy.3-9 There are few, but increasing reports of robotic
lobectomy using the purported benefits of 3-dimensional
imaging and wristed instrumentation for minimally invasiveTABLE 2. Perioperative results
Category Result
Operative time (min)* 206 (110-383)
Chest tube (d)* 3 (1-23)
Length of stay (d)* 5 (2–28)
Complications
None 243 (75%)
Minor 70 (21.5%)
Major 12 (3.7%)
Perioperative mortality 1 (0.3%)
Pathologic stagey
IA 176 (54%)
IB 72 (22%)
IIA 41 (13%)
IIB 15 (5%)
IIIA 21 (6%)
Tumor size (cm)* 2.2 (0.7-10.2)
Lymph node stations removed* 5 (2-8)
*Median (range). ySeventh edition of the TNM classification.
The Journal of Thoracic and Calung resection.12-15 Previous robotic series have shown
comparable perioperative results to those seen with VATS
lobectomy, and our current experience again affirms that
robotic lobectomy is feasible and safe with a short chest
tube duration and length of stay, as well as low major
morbidity (3.7%) and in-hospital mortality (0.3%) rates.
The conversion rate to thoracotomy of 8.3% and the rea-
sons for conversion were consistent with the largest series
of VATS lobectomies, where the rate varies anywhere
from 2.5% to 17.5%.3-5 Both conversion rates (11% [17/
150] vs 5.7% [10/175]) and median operative times (210
minutes vs 195 minutes) were lower after the first 50
cases at each center. This was quite similar to 1 author’s
(G.V.) previous experience demonstrating a 43-minute
decrease in operative time after the initial 18 cases.15 No
catastrophic episodes of hemorrhage were encountered,
and bleeding episodes were easily managed through stan-
dard minimally invasive surgical strategies. In those cases
of hemorrhage requiring conversion to thoracotomy, ade-
quate control was obtained through the use of sponge stick
tamponade through the utility incision while the robot
was removed and the wound opened. In addition to feasibil-
ity data, our study has unique aspects not previously
demonstrated.
First, it is the largest experience of totally robotic lobec-
tomies reported to date. The first series reported by Melfi
and coauthors12 contained 23 patients and focused primar-
ily on technical aspects, as did a subsequent, larger series
(n ¼ 34) from Park, Flores, and Rusch.13 Gharagozloo
and colleagues14 described a series of 100 consecutive pa-
tients but used a hybrid VATS-robotic technique in which
the mediastinal node and hilar dissection were performed
robotically followed by conventional VATS ligation of the
hilar structures.
Second, it is a multicenter, international experience with
1 center in the United States and 2 in Italy using similar pa-
tient selection criteria, surgical technique, and prospective
evaluation of perioperative and long-term outcome. The pa-
tient population was relatively uniform, composed largely
of patients with early-stage disease without prior treatment
and with adequate cardiopulmonary reserve for lobectomy.rdiovascular Surgery c Volume 143, Number 2 385
FIGURE 1. A, Robotic lobectomy overall survival. B, Stage-specific sur-
vival. CI, Confidence intervals.
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SAs detailed in previous technical publications, each center
used a fully robotic technique that conformed to the
CALGB 39802 consensus criteria for minimally invasive
lobectomy,12,13,15 and each of the authors performed
systematic hilar and mediastinal lymph node dissection.
In 2 of the centers a 4-arm technique was used (a fourth,
small non–rib-spreading incision was used for placement
of the fourth robotic arm for retraction), whereas a 3-arm
approach was used at the third center. This minor difference
in techniquewas likely of no clinical significance. Although
the majority of tumors were small, there were larger lesions
including a 10.2-cm tumor. Because a non–rib-spreading
utility incision was used, adequate retraction was able to386 The Journal of Thoracic and Cardiovascular Surgbe achieved easily either by robotic instrumentation alone
or by the bedside assistant.
Third, this report is the first to look at the long-term on-
cologic outcome of robotic lobectomy for early NSCLC.
The overall and stage-specific survivals are consistent
both with the largest recent series of VATS lobectomies4,5
and the data used for the seventh edition of the lung
cancer staging system, which was largely derived from
conventional open surgery.17 Onaitis and colleagues4 re-
ported 2-year overall survival of 80% and stage-specific
survivals of 85% for stage I and 77% for stages II and
higher in a cohort of 500 patients undergoing VATS lobec-
tomy for clinical early-stage disease. Goldstraw and coau-
thors17 reported 5-year overall survivals of 73% and 58%
for stages IA and IB, respectively, and 46% and 36% for
stages IIA and IIB. These data are very consistent with those
observed in this large robotic series in which the 5-year sur-
vival for stage II patients was 49%. The excellent 5-year
survival in pathologic stage I in this study (IA, 91%; IB,
88%) is likely related to the fact that the median tumor
size was small (2.2 cm).
There are, however, limitations of this study and ques-
tions regarding the role of robotic technology in thoracic
surgery. Inasmuch as this is a retrospective review, there
are inevitable biases in patient selection and unknown dif-
ferences between centers despite the fact that the patient
characteristics and surgical techniques appear similar. An-
other limitation is the lack of other short- and long-term
outcome measures, such as postoperative pain, respiratory
function, rates of postthoracoscopy pain, and quality of
life. Last, a comparative arm of VATS and/or thoracotomy
patients is lacking. If use of robotic technology for tho-
racic surgical procedures increases, it will be important
for future studies to attempt to discern differences between
robotic and VATS approaches with respect to important
outcomes, such as postoperative pain, quality of life, and
cost.
With respect to the latter, cost of robotic technology in
times of increasing health care expenditures is a real issue.
There is no question that even without taking into consider-
ation the amortized costs of these systems, robotics adds ad-
ditional cost compared with conventional VATS.18
However, a recent analysis of the voluntary Society of Tho-
racic Surgery database demonstrated that although the per-
centage of all lobectomies done by VATS has been
increasing, overall only 20%were performed by VATS dur-
ing the 3-year study period ending in 2006.10 Furthermore,
there are some data, such as an even more recent analysis of
a nonvoluntary national insurance database revealing that
less than 6% of lobectomies were done by VATS, that sug-
gest that the overall adoption rate of VATS lobectomy may
in fact be lower in nonacademic, community-based set-
tings.11 If robotic technology can lead to greater adoption
of a minimally invasive approach in a safe and appropriateery c February 2012
Park et al General Thoracic Surgerymanner, the added cost may be justified by all the attendant
benefits over traditional open surgery.
Robotic lobectomy is a feasible, safe, and oncologically
sound surgical treatment for early-stage lung cancer. The
technique is reproducible across multiple centers and yields
results consistent with the best seen with conventional
VATS. It should not be considered experimental, but an ac-
cepted minimally invasive thoracic surgical technique. Fu-
ture evaluation of differences between robotic versus
VATS versus thoracotomy approaches to thoracic diseases
is warranted.G
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Dr Thomas A. D’Amico (Durham, NC). Robotics has been
used in numerous surgical procedures, but, with few exceptions,
this technologic advance has not translated into improved out-
comes. Many robotic applications have been unveiled as the man-
ifestation of a tool—sometimes a marketing tool—in search of an
application. The principal advantages of robotic assistance in sur-
gery are the greater degree of instrumental articulation and motion
scaling. However, despite these recognized technical advantages,
the demonstration of superior outcomes has been disappointing.
As well, several disadvantages of the robotic system have been
proven, including the lack of tactile feedback, personnel commit-
ment, cost of the robot and its instruments, and the length of the
procedures. In addition, the instrumentation that is currently avail-
able for use robotically is still limited.
The multi-institutional retrospective review by Park and his col-
leagues represents the largest robotic lobectomy series to date;
more than 325 consecutive patients underwent robotic lobectomy
for early-stage disease at the 3 institutions. The conversion rate
was, admirably, relatively low, only 8%, with reasonable morbid-
ity, consistent with thoracoscopic lobectomy series in the litera-
ture. The length of stay was longer, perhaps with the inclusion
of patients in Europe. Finally, stage-specific survival was excel-
lent, also consistent with both open and thoracoscopic experiences,
including patients with stage IIIA disease. Thus, the authors have
demonstrated that robotic lobectomy for early-stage disease is ef-
fective, feasible, oncologically sound, and comparable, but not su-
perior, to thoracoscopic lobectomy.
Less clear is the compared effectiveness of the robot vis-a-vis
thoracoscopic lobectomy. Although thoracoscopic lobectomy has
been demonstrated to be superior to open lobectomy in terms of
outcomes and costs, analyses of the costs relating to robotic lobec-
tomy suggest that the procedure is approximately $2000 more ex-
pensive than open and $4000 more expensive than VATS. In light
of these issues, I have 3 questions, and I will ask them 1 at a time.
How should the cost of robotic lobectomy be considered in the
evaluation of its effectiveness? Unlike some technologies in which
cost has decreased over the evolution of the technology, the oppo-
site seems to be happening with robotics; costs continue to in-
crease, both fixed and variable. Although the promise that this
technology as the future of all surgery has been adamantly put for-
ward by others, I believe that a more logical response is required to
adequately assess the effectiveness of robotic lobectomy.
Dr Park. Thank you for that analysis and question.
Cost is an extremely important feature, and you are right, robot-
ics is a technology. I think it is critical to compare robotics (a min-
imally invasive modality) to thoracotomy, which is still the
standard approach throughout the world. You stated that studies
have shown that robotics is more expensive than thoracotomy,
but I think that does remain to be seen and proven. We are going
to be presenting a paper at the meeting of The International Society
for Minimally Invasive Cardiothoracic Surgery (ISMICS) next
month that compares costs associated with VATS versus robotic
versus thoracotomy, which I believe will begin to address this. Irdiovascular Surgery c Volume 143, Number 2 387
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Sthink a critical issue is this: does robotics allowing us to transition
from thoracotomy to minimally invasive approaches to early-stage
lung cancer in the appropriate patients? Therefore, any cost anal-
ysis has to take that into account. If you are able to transition more
surgeons into doing oncologically sound and safe procedures min-
imally invasively through the use of robotic technology, then per-
haps those costs are justified. However, all things being
considered, I think if you were to compare VATS nonrobotic and
robotic in the most excellent hands, then yes, there’s no question
that robotics is more expensive. Whether that cost is justified de-
pends on whether we could have most of our thoracic surgeons
or people who do thoracic surgery do it by VATS.
Dr D’Amico. The issue of the transition brings up my second
question. Inasmuch as thoracic surgeons, both in and out of train-
ing, are not adequately exposed to robotics, howdoyou recommend
that surgeons take on this new technology to assure competency?
Dr Park. That question is in parallel to questions about ad-
vancedminimally invasive surgery in general. Atmost of our excel-
lent training programs, the trainees are getting more and more
exposed to advanced minimally invasive surgery, but that still
leaves a whole population of surgeons who only know how to do
thoracotomies, and they are faced with the same challenge of hav-
ing to figure out how to do advancedVATS surgery, let alone robotic
surgery. I think it is incumbent on major organizations, like The
American Association for Thoracic Surgery and The Society of
Thoracic Surgeons, to come up with guidelines for defining the ap-
propriate use of such technologies and the minimum credentialing
so that surgeons can get trained and be deemed to be qualified in
these procedures. We need the organizations to come forth and de-
finewhat the procedures are, to define how people can get trained in
those procedures, and then to allow hospitals throughout the coun-
try and the world to determine how they can credential their sur-
geons and deem that they are qualified to do these procedures.
Dr D’Amico. I do not have an answer to my own question, but
surgical associations have never done that for any other procedure,
so I do not see The American Association for Thoracic Surgery or
The Society of Thoracic Surgeons or the Board coming up and say-
ing: This is how you need to do it. It is going to have to come from
somewhere, but I would not necessarily expect that the associa-
tions would do it.
Finally, please comment on the impact of new robotic technol-
ogy that is on the frontier: single-port entry, new energy sources,
in-line staplers, infrared optics for sentinel node technology, sim-
ulation programs, and others. How do you think these new ad-
vances will translate into improved effectiveness for lobectomy?
Dr Park. I think simulation, as you mentioned, is one of the
critical new technologies that is going to allow trainees or anybody
who is established who wants to learn this technology and ad-
vanced minimally invasive techniques to do this in a more safe en-
vironment, to get practice without putting patients at harm. There
is going to be stapling technology to allow direct control of the sta-
pler. I think using the 3-dimensional optics is going to be a huge
benefit, because even with some of the newer-technology staplers,
most of us still feel some trepidation passing the staplers behind
the hilar structures, and I think that is only going to help. Certainly,
other instrumentation to help with retraction, exposure, and suc-
tioning will all help. However, as you alluded to before, they are
going to potentially result in increased costs. I think we have to388 The Journal of Thoracic and Cardiovascular Surgevaluate these critically and decide which are necessary, and that
will make these procedures safer and more feasible.
Dr Scott J. Swanson (Boston, Mass). What I would like to do
now is just put on your hat of senior lung cancer surgeon. With the
lung cancer screening trial coming and the fact that VATS lobec-
tomies have gone from about 10% to 30%, how would you use
this technology across the country? Do you think it is realistic
that all hospitals should have a robot and everyone should learn
it? Should there be centers where people go for robotic surgery?
How realistically should we get more minimally invasive opera-
tions to our patients?
Dr Park. We have to remember that the 30% number is from
The Society of Thoracic Surgeons voluntary database. There are
other nonvoluntary databases that show that some rates of VATS
lobectomy are as low as 6%. I am not sure that we are seeing an
explosion of VATS lobectomy as a technique. I would love to think
that that is true.
Your question is very similar to Dr D’Amico’s.
As with any other technology, we need to identify centers of ex-
cellence and concentrate on trying to bring people to see what is
going on in those centers, to organize training courses so that peo-
ple can gain exposure to minimally invasive techniques and decide
for themselves whether they are reasonable options and whether
they do fit with their armamentarium. With increasing early-stage
disease, increasing minimally invasive approaches is warranted
and necessary, not only for the benefit of the hospital but for the
benefit of the health care system in general in terms of allowing pa-
tients to recover quicker, getting them out of the hospital, and get-
ting them back to their preoperative state.
DrK. AdamLee (Cherry Hill, NJ). In your data did you see any
difference between a 3-arm approach and a 4-arm approach?
Looking forward, do you see the robotic assisted technique transi-
tioning an open thoracotomy surgeon to become more involved in
minimally invasive surgery? Do you see some of those positive re-
sults of the robotics procedure helping to reach that goal?
Dr Park. There was no real difference between 3-arm and
4-arm techniques. Again, 2 of the centers had a 4-arm technique
and 1 had a 3-arm technique, but basically there was just 1 addi-
tional incision. All of the unified themes of non–rib-spreading
and using videoscopic guidance were the same. There was no
real difference clinically.
It is really hard to know whether robotics can help traditional
thoracotomy surgeons transition to minimally invasive. I think
we have to study that, if it is feasible, prospectively. I know, again,
that VATS lobectomy and the excellent results that are published
are being done so by essentially a core group of outstanding prac-
titioners at great centers. The question is not whether robotics is
the answer as opposed to VATS; the question is how we can appro-
priately use technology to increase the percentage of minimally in-
vasive procedures that are done appropriately.
Dr Todd L. Demmy (Buffalo, NY). Another surgeon who per-
formed many robotic lobectomies commented that a large tumor
in the upper lobe is a hassle, and this gets to the issuewith the robot
having just 1 implementing arm per port. With thoracoscopy, you
can use multiple retractors from a single port and handle that large
tumor. In your study, did you notice any effect of big tumors in the
upper lobe? You had a 10-cm specimen. Was that in the lower
lobe?ery c February 2012
Park et al General Thoracic SurgeryDr Park.All of the techniques had a utility incision and most of
the assistants were able to retract through the utility incision. I am
aware of no increased difficulty with larger tumors in these robotic
series.
Dr Joachim Schirren (Wiesbaden, Germany). The patients in
stage IA and 1B are nearly cured, but in stage II, you have resultsThe Journal of Thoracic and Cayou can reach in open surgery in stage III. Therefore, my question
is how many systemic relapses did you have and how many local
relapses did you find in this stage?
Dr Park. Only 9 of the 32 patients had local-only relapse, and
the majority of the 32 patients had either local plus distant or dis-
tant relapse. It was really systemic recurrence.rdiovascular Surgery c Volume 143, Number 2 389
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